Market capitalization | $77.03m |
Enterprise Value | $44.63m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.71 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-31.90m |
Free Cash Flow (TTM) Free Cash Flow | $-30.58m |
Cash position | $47.85m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
3 Analysts have issued a Cortexyme, Inc. forecast:
3 Analysts have issued a Cortexyme, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.47 -0.47 |
683%
683%
|
|
EBITDA | -31 -31 |
26%
26%
|
EBIT (Operating Income) EBIT | -32 -32 |
27%
27%
|
Net Profit | -53 -53 |
90%
90%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Dirk Thye |
Employees | 32 |
Founded | 2012 |
Website | quincetx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.